Intellectual Property India Publishes Patent Application for 'A Novel Quinoline-pyrimidine Hybrid Derivatives As Selective Egfr Inhibitors For The Treatment Of Non-Small Cell Lung Cancer And Process For Their Preparation' Filed by Dr. Hemalatha K; Mr. Kumaraswamy B; and Dr. Gurubasavaraja Swamy P M

MUMBAI, India, May 1 -- Intellectual Property India has published a patent application (202641049621 A) filed by Dr. Hemalatha K; Mr. Kumaraswamy B; and Dr. Gurubasavaraja Swamy P M, Bengaluru, Karnataka, on April 18, for 'a novel quinoline-pyrimidine hybrid derivatives as selective egfr inhibitors for the treatment of non-small cell lung cancer and process for their preparation.'

Inventor(s) include Dr. Hemalatha K; Mr. Kumaraswamy B; and Dr. Gurubasavaraja Swamy P M.

The application for the patent was published on May 1, under issue no. 18/2026.

According to the abstract released by the Intellectual Property India: "The present invention relates to novel quinoline-pyrimidine hybrid derivatives designed as selective inhibitors of Epidermal Growth Factor Receptor (EGFR) kinase for the treatment of non-small cell lung cancer (NSCLC). The disclosed compounds comprise a 2-chloroquinoline moiety linked to a substituted pyrimidine scaffold and demonstrate enhanced binding affinity toward the ATP-binding site of EGFR. The lead compounds exhibit significant in-vitro cytotoxic activity against A549 lung adenocarcinoma cell lines and show improved potency compared to standard EGFR inhibitors. The invention further provides methods for synthesis, structural characterization using spectroscopic techniques, pharmaceutical compositions comprising the compounds, and their therapeutic application in the management of EGFR-driven malignancies."

Disclaimer: Curated by HT Syndication.